Norinchukin Bank The Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Norinchukin Bank The increased its holdings in Regeneron Pharmaceuticals by 44.2%, now owning 8,378 shares worth approximately $5.31 million.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for the last quarter, exceeding analysts' expectations of $8.43, with a net margin of 31.37%.
• The company will pay a quarterly dividend of $0.88 per share on September 3rd, representing an annualized yield of 0.6%.

Norinchukin Bank The increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 44.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,378 shares of the biopharmaceutical company's stock after purchasing an additional 2,568 shares during the period. Norinchukin Bank The's holdings in Regeneron Pharmaceuticals were worth $5,314,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $27,000. Tompkins Financial Corp purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $32,000. Finally, Curat Global LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $32,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

REGN has been the topic of a number of analyst reports. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a research report on Friday, August 1st. BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Morgan Stanley reaffirmed an "overweight" rating and issued a $761.00 price objective (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $829.65.

Regeneron Pharmaceuticals Stock Down 1.5%

Shares of REGN traded down $8.68 during mid-day trading on Friday, hitting $589.48. 1,438,624 shares of the company traded hands, compared to its average volume of 1,026,661. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $62.48 billion, a PE ratio of 14.86, a price-to-earnings-growth ratio of 1.96 and a beta of 0.33. The business has a 50 day moving average of $550.48 and a 200 day moving average of $590.42.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the prior year, the company posted $11.56 earnings per share. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.